A Randomized Trial of the Effect of a GnRH Analogue Injection on Ghrelin Levels in Girls

Abstract

<b><i>Introduction:</i></b> Ghrelin concentrations decline during puberty by an unclear mechanism. Acylated ghrelin (AG) is unstable in sampling tubes, but no standardized sampling protocol exists. We hypothesized that ghrelin levels decrease as a consequence of increased gonadotropin-releasing hormone (GnRH) signalling and that the addition of a protease inhibitor to sampling tubes preserves the AG levels. <b><i>Methods:</i></b> In this randomized, placebo-controlled, cross-over study, 13 girls with suspected central precocious puberty were included. They performed an adjusted GnRH stimulation test twice and were given Relefact LHRH^® (100 μg/m²) or saline in a randomized order. Blood was sampled repeatedly for 150 min for the analysis of hormone concentrations. Oestradiol levels were only measured at baseline. The protease inhibitor 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF) was added to the sampling tubes. Specific ELISA kits were used for the analysis of AG and desacylated ghrelin (DAG) levels. <b><i>Results:</i></b> Neither AG nor DAG levels changed after GnRH analogue injection in comparison to saline. The addition of AEBSF preserved AG levels (650.1 ± 257.1 vs. 247.6 ± 123.4 pg/mL, <i>p</i> &#x3c; 0.001) and decreased DAG levels (51.9 [12.5–115.7] vs. 143.5 [71.4–285.7] pg/mL, <i>p</i> &#x3c; 0.001). Both AG and DAG levels were inversely associated with insulin levels (<i>r</i> = −0.73, <i>p</i> = 0.005, and <i>r</i> = −0.78, <i>p</i> = 0.002, respectively). AG levels were inversely associated with oestradiol levels (rho = −0.57, <i>p</i> = 0.041). <b><i>Conclusion:</i></b> Ghrelin levels do not decrease following a pharmacological dose of a GnRH analogue in the short term in girls. Addition of a protease inhibitor to the sampling tubes decreases AG degradation, resulting in preserved AG and decreased DAG levels.